|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
264,900,000 |
Market
Cap: |
8.27(B) |
Last
Volume: |
49,305,461 |
Avg
Vol: |
6,977,806 |
52
Week Range: |
$12.46 - $31.23 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 606 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
351,008 |
4,785,085 |
4,785,085 |
Total Sell Value |
$0 |
$10,362,565 |
$86,338,289 |
$86,338,289 |
Total People Sold |
0 |
4 |
5 |
5 |
Total Sell Transactions |
0 |
7 |
26 |
26 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
|
2023-08-04 |
4 |
OE |
$4.55 |
$5,901,760 |
D/D |
1,104,218 |
1,545,667 |
|
- |
|
Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
|
2023-08-03 |
4 |
S |
$16.61 |
$16,942,200 |
D/D |
(1,020,000) |
441,449 |
|
-79% |
|
Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
|
2023-08-03 |
4 |
OE |
$4.55 |
$4,642,932 |
D/D |
1,020,000 |
1,461,449 |
|
- |
|
Lentini Renee |
PRIN. FIN & ACCTG. OFF. |
|
2023-08-03 |
4 |
OE |
$2.31 |
$124,907 |
D/D |
51,033 |
73,876 |
|
- |
|
Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
|
2023-08-02 |
4 |
S |
$18.12 |
$77,101 |
D/D |
(4,255) |
10,960 |
|
-70% |
|
Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
|
2023-08-02 |
4 |
OE |
$4.92 |
$20,935 |
D/D |
4,255 |
15,215 |
|
- |
|
Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
|
2023-08-02 |
4 |
S |
$17.45 |
$17,371,535 |
D/D |
(995,157) |
441,449 |
|
-70% |
|
Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
|
2023-08-02 |
4 |
OE |
$4.55 |
$4,527,964 |
D/D |
995,157 |
1,436,606 |
|
- |
|
Lentini Renee |
PRIN. FIN & ACCTG. OFF. |
|
2023-08-02 |
4 |
S |
$17.55 |
$2,602,261 |
D/D |
(148,277) |
22,843 |
|
-70% |
|
Lentini Renee |
PRIN. FIN & ACCTG. OFF. |
|
2023-08-02 |
4 |
OE |
$2.31 |
$677,777 |
D/D |
148,277 |
171,120 |
|
- |
|
Arbuckle Stuart A |
|
|
2023-06-30 |
4 |
A |
$18.87 |
$13,115 |
D/D |
695 |
4,112 |
|
- |
|
Thackray Helen M. |
|
|
2023-06-30 |
4 |
A |
$18.87 |
$7,491 |
D/D |
397 |
2,350 |
|
- |
|
Berkenblit Anna |
SVP & CHIEF MEDICAL OFFICER |
|
2023-06-30 |
4 |
A |
$4.05 |
$13,219 |
D/D |
3,264 |
113,935 |
|
- |
|
Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
|
2023-06-30 |
4 |
A |
$4.05 |
$11,385 |
D/D |
2,811 |
86,156 |
|
- |
|
Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
|
2023-06-30 |
4 |
A |
$4.05 |
$21,226 |
D/D |
5,241 |
441,449 |
|
- |
|
Lentini Renee |
V.P.-FIN., PRIN. ACCTG. OFF. |
|
2023-06-30 |
4 |
A |
$4.05 |
$12,940 |
D/D |
3,195 |
22,843 |
|
- |
|
Goldberg Mark Alan |
|
|
2023-06-30 |
4 |
A |
$18.87 |
$16,870 |
D/D |
894 |
59,088 |
|
- |
|
Coen Stacy Ann |
SVP & CHIEF BUSINESS OFFICER |
|
2023-06-30 |
4 |
A |
$4.05 |
$15,358 |
D/D |
3,792 |
10,960 |
|
- |
|
Lentini Renee |
V.P.-FIN., PRIN. ACCTG. OFF. |
|
2022-12-30 |
4 |
A |
$3.92 |
$5,296 |
D/D |
1,351 |
19,648 |
|
- |
|
Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
|
2022-12-30 |
4 |
A |
$3.92 |
$4,434 |
D/D |
1,131 |
83,345 |
|
- |
|
Berkenblit Anna |
SVP & CHIEF MEDICAL OFFICER |
|
2022-12-30 |
4 |
A |
$3.92 |
$1,709 |
D/D |
436 |
110,671 |
|
- |
|
Char Daniel |
SVP & CHIEF LEGAL OFFICER |
|
2022-11-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
-30% |
|
Harrington-Smith Kristen |
SVP & CHIEF COMMERCIAL OFFICER |
|
2022-11-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
Wingrove Theresa |
SVP OF REGULATORY AFFAIRS |
|
2022-06-30 |
4 |
A |
$3.83 |
$10,117 |
D/D |
2,645 |
82,214 |
|
- |
|
Enyedy Mark J |
CHIEF EXECUTIVE OFFICER |
|
2022-06-30 |
4 |
A |
$3.83 |
$12,783 |
D/D |
3,342 |
436,208 |
|
- |
|
257 Records found
|
|
Page 4 of 11 |
|
|